As mentioned in this literature review, naringenin has been shown to exert potential pharmacological activities against multiple pathological stages of COPD through various signaling pathways such as PI3K/AKT, STAT3, p38 MAPK, and ERK pathways. This evidence concerns the gene AKT1 and chronic obstructive pulmonary disease.